Stimcell Energetics Inc.

Stimcell Energetics Inc.

Overview

Stimcell Energetics develops and markets the eBalance® microcurrent energy therapy (MEY) platform. eBalance® delivers subsensory microampere electrical signals through the skin to target peripheral nerves and is intended to support general wellness and provide temporary relief of pain. The platform supports professional and consumer use via two device systems: eBalance® Pro for clinical settings and eBalance® Home for at-home use.

Core technology and product lineup

• eBalance® is the company’s MEY platform and is the foundation for:
  • eBalance® Pro System (professional, clinical use)
  • eBalance® Home System (consumer, at-home use)
• Both systems use a centralized eBalance® Console with three pre-programmed algorithms: Wellness, Pain Management, Dual.
  • Pro accessories: Hand Bars, Foot Plates, and Pen Probes
  • Home accessories: Hand Bars and Foot Plates
• The company plans to expand into specialized software and treatment options, dependent on funding.

Regulatory status and manufacturing

• Certifications: ISO 13485:2016 and MDSAP (Stage 2 audit completed in 2020).
• Health Canada: Class II Medical Device Licenses for eBalance® Home and Pro were issued in July/August 2020 and suspended in 2023.
• U.S. FDA: A 510(k) submission was not finalized and the related process was withdrawn.
• Manufacturing and design: Development and manufacturing have included multiple device iterations and adherence to CSA, CE, and UL standards. A redesigned, smaller consumer eBalance® Home unit (eBalance Wellness) is being developed with ADM Tronics Unlimited, Inc., targeted for completion in fall 2025 and market readiness in early 2026.

Intellectual property

• EBALANCE is a registered trademark in the U.S., U.K., EU, and Canada.
• The eBalance® technology is not patented.

Market focus and commercial arrangements

• Primary market focus: diabetes care and management of diabetes-related complications, and general pain management.
• Distribution/licensing history with Live Current Media (LIVC):
  • Previously held an exclusive worldwide distribution agreement with Direct Rights for end-user sales.
  • Original terms included a one-time $250,000 fee and minimum orders contingent on FDA clearance.
  • In 2020, Stimcell reacquired Direct Rights from LIVC in exchange for royalties capped at $507,500 (comprised of $25 per device up to 3,500 devices and $5 per month for devices generating recurring revenue, or a one-time alternative of $145 per device if monthly revenue is cancelled).
• Competitive context: faces competition from pharmaceutical and medical device companies in the broader pain and diabetes management markets.

Clinical program and outcomes

• Observational Health Canada study: 30 subjects (Type 1 and Type 2 diabetes) over three months; final report submitted January 2018.
• Safety: No significant adverse events reported.
• Efficacy signals (reported changes):
  • Fasting plasma glucose: decreased 12.3% (from 10.5 to 9.2 mmol/L)
  • Plasma insulin: decreased 48% (from 168 to 86 pmol/L)
  • HbA1c: decreased 0.16% (from 8.36% to 8.20%)
  • Blood pressure: systolic reduced from 142 to 128 mmHg; diastolic from 78 to 70 mmHg
• Additional observations: qualitative improvements in neuropathy, wound healing, and pain in extremities for some subjects.
• Further clinical trials were halted due to funding constraints.

Corporate and operations

• Corporate structure:
  • Incorporated in Nevada (U.S.) with a Canadian subsidiary, Cell MedX (Canada) Corp., in British Columbia.
  • On November 1, 2024, completed a 1-for-15 reverse stock split, reduced authorized capital to 500,000,000 shares, and outstanding shares to 19,816,272. The company name changed to Stimcell Energetics Inc.
• Personnel: No formal employees other than executive officers who provide services as independent consultants. Engineering and medical/technical work is contracted as needed.
• Offices: Principal executive office at 555 - 1130 West Pender Street, Vancouver, BC, Canada, and a virtual office in Carson City, Nevada.
• R&D and manufacturing partnerships include ADM Tronics Unlimited and earlier engagements with Western Robotics and other contract manufacturers/engineering partners.

Financial and funding status (as of May 31, 2026)

• Revenues: Minimal to date; revenue-generating activities related to eBalance Home and Pro were suspended after Health Canada license suspensions in 2023.
• Accumulated deficit: approximately $11,756,931 since inception.
• Liquidity: The company reports a working capital deficiency and limited resources; substantial external financing is required to continue development and operations.
• Debt and related-party obligations: Approximately $1,498,798 due to related parties and notes payable (including $665,321 due to related parties and $833,477 in notes/payables). Related-party debt has been partially settled through share issuances in the past.
• Equity and market: Plans to raise additional capital through share offerings, which would dilute current shareholders. The company’s securities are considered penny stock with limited trading liquidity.
• Currency exposure: Financial reporting in U.S. dollars with a portion of expenses in Canadian dollars and no hedging.

Key takeaways

• Business: Develops and markets the eBalance® MEY platform for wellness, pain relief, and diabetes-related management, and is transitioning toward a consumer-oriented wellness device.
• Regulatory and commercial status: Canadian device licenses were suspended in 2023; U.S. FDA clearance was not finalized; commercial activity is limited pending further funding and regulatory progress.
• Financial position: Large cumulative deficit, working capital shortfall, and notable related-party obligations; continued operations will depend on securing additional financing.
• Operations: Executive officers and contractors manage operations; headquarters in Vancouver with a Canadian subsidiary; corporate restructuring and a reverse stock split completed in 2024.